Diabetes Mellitus in Children and Adolescents

Clinical Diabetes

Volumn , Issue , 2006, Pages 505-521

  Weinzimer, Stuart A ^a,b   Tamborlane, William V ^a,c  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b YALE NEW HAVEN HOSPITAL   (United States)

^c YALE NEW HAVEN CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84882492118     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4160-0273-4.50042-4     Document Type: Chapter

References (59)

1. Sperling MA Diabetes mellitus. Pediatric Endocrinology 2002, 323-366. WB Saunders, Philadelphia. M.A. Sperling (Ed.).
2. Karvonen M, Vilik-Kajander M, Moltchanova E, et al. Incidence of childhood type 1 diabetes worldwide. Diabetes Care 2000, 23:1516-1526.
3. Chase HP, Crews KR, Garg S, et al. Outpatient management vs. in-hospital management of children with new-onset diabetes. Clin Pediatr 1992, 31:450-456.
4. Vajo Z, Fawcett J, Duckworth WC Recombinant DNA technology in the treatment of diabetes: Insulin analogs. Endocr Rev 2001, 22:706-717.
5. Lepore M, Pampanelli S, Fanelli C, et al. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and Ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes 2000, 49:2142-2148.
6. Schober E, Schoenle E, Van Dyk J, et al. Comparative trial between insulin glargine and NPH insulin in children and adolescents with type 1 diabetes mellitus. J Pediatr Endocrinol Metab 2002, 15:369-376.
7. Murphy NP, Keane SM, Ong KK Randomized cross-over trial of insulin glargine plus lispro or NPH insulin plus regular human insulin in adolescents with type 1 diabetes on intensive insulin regimens. Diabetes Care 2003, 26:799-804.
8. Yki-Jarvinen H, Koivisto VA Natural course of insulin resistance in type 1 diabetes. N Engl J Med 1986, 315:224-230.
9. The effect of intensive diabetes treatment in the DCCT on residual insulin secretion in IDDM. Ann Intern Med 1998, 128:517-523. The DCCT Research Group.
10. Attia N, Caprio S, Jones TW, et al. Changes in free insulin-like growth factor-1 and leptin concentrations during acute metabolic decompensation in insulin withdrawn patients with type 1 diabetes. J Clin Endocrinol Metab 1999, 84:2324-2328.
11. Koves IH, Neutze J, Donath S, et al. The accuracy of clinical assessment of dehydration during diabetic ketoacidosis in childhood. Diabetes Care 2004, 27:2485-2487.
12. Katz MA Hyperglycemia-induced hyponatremia. N Engl J Med 1973, 289:843-844.
13. Harris GD, Fiordalisi I, Harris WL, et al. Minimizing the risk of brain herniation during treatment of diabetic ketoacidemia: A retrospective and prospective study. J Pediatr 1990, 117:22-31.
14. Harris GD, Fiordalisi I Physiologic management of diabetic ketoacidemia: A 5-year prospective pediatric experience in 231 episodes. Arch Pediatr Adolesc Med 1994, 148:1046-1052.
15. Ham MR, Okada P, White PC Bedside ketone determination in diabetic children with hyperglycemia and ketosis in the acute care setting. Pediatric Diabetes 2004, 5:39-43.
16. Glaser N, Barnett P, McCaslin I, et al. Risk factors for cerebral edema in children with diabetic ketoacidosis. N Engl J Med 2001, 344:264-269.
17. Duck SC, Wyatt DT Factors associated with brain herniation in the treatment of diabetic ketoacidosis. J Pediatr 1988, 113:10-14.
18. Bello FA, Sotos JF Cerebral edema in diabetic ketoacidosis in children. Lancet 1990, 336:64.
19. Dunger DB, Sperling MA, Acerini CL, et al. ESPE/LWPES consensus statement on diabetic ketoacidosis in children and adolescents. Arch Dis Child 2004, 89:188-194.
20. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993, 329:977-986. Diabetes Control and Complications Trial Research Group.
21. Effect of intensive diabetes treatment on the development and progression of long-term complications in adolescents with insulin-dependent diabetes mellitus: Diabetes Control and Complications Trial. J Pediatr 1994, 125:177-188. Diabetes Control and Complications Trial Research Group.
22. Beneficial effects of intensive therapy of diabetes during adolescence: Outcomes after the conclusion of the Diabetes Control and Complications Trial (DCCT). J Pediatr 2001, 139:804-812. Diabetes Control and Complications Trial (DCCT)/ Epidemiology of Diabetes Interventions and Complications (EDIC) Research Group.
23. Grey M, Boland EA, Davidson M, et al. Coping skills training for youth on intensive therapy has long lasting effects on metabolic control and quality of life. J Pediatr 2000, 137:107-114.
24. Ahern JH, Boland EA, Doane R, et al. Insulin pump therapy in pediatrics: A therapeutic alternative to safely lower HbA1c levels across all age groups. Pediatric Diabetes 2002, 3:10-15.
25. Doyle EA, Weinzimer SA, Steffen AT, et al. A randomized, prospective trial comparing the efficacy of continuous subcutaneous insulin infusion with multiple daily injections using insulin glargine. Diabetes Care 2004, 27:1554-1558.
26. Weinzimer SA, Doyle EA, Steffen AT, et al. Rediscovery of insulin pump treatment of childhood type 1 diabetes. Minerva Med 2004, 95:85-92.
27. Zinman B, Tildesley H, Chiasson JL, et al. Insulin lispro in CSII: Results of a double-blind crossover study. Diabetes 1997, 46:440-443.
28. Bode BW, Strange P Efficacy, safety, and pump compatibility of insulin aspart used in continuous subcutaneous insulin infusion therapy in patients with type 1 diabetes. Diabetes Care 2001, 24:69-72.
29. Boland EA, Grey M, Fredrickson L, et al. CSII: A "new" way to achieve strict metabolic control, decrease severe hypo-glycemia and enhance coping in adolescents with type I diabetes. Diabetes Care 1999, 22:1779-1784.
30. Weinzimer SA, Ahern JH, Boland EA, et al. Persistence of benefits of continuous subcutaneous insulin infusion in very young children with type 1 diabetes: A follow-up report. Pediatrics 2004, 114:1601-1605.
31. Attia N, Jones TW, Holcombe J, et al. Comparison of human regular and lispro insulins after interruption of continuous subcutaneous insulin infusion and in the treatment of acutely decompensated IDDM. Diabetes Care 1998, 21:817-821.
32. Celona-Jacobs N, Weinzimer SA, Rearson MA, et al. Insulin pump therapy in children: A cautionary tale. Diabetes 2001, 50(Suppl 2):A67.
33. Bina DM, Anderson RL, Johnson ML, et al. Clinical impact of prandial state, exercise, and site preparation on the equivalence of alternative-site blood glucose testing. Diabetes Care 2003, 26:981-985.
34. Boland EA, DeLucia M, Brandt C, et al. Limitations of conventional methods of self blood glucose monitoring: Lessons learned from three days of continuous glucose monitoring in pediatric patients with type I diabetes. Diabetes Care 2001, 24:1858-1862.
35. Chase HP, Kim LM, Owen SL, et al. Continuous subcutaneous monitoring in children with type 1 diabetes. Pediatrics 2001, 107:222-226.
36. Kaufman FR, Gibson LC, Halvorson M, et al. A pilot study of the continuous glucose monitoring system: Clinical decisions and glycemic control after its use in pediatric type 1 diabetic subjects. Diabetes Care 2001, 24:2030-2034.
37. Chase HP, Roberts MD, Wightman C, et al. Use of the GlucoWatch biographer in children with type 1 diabetes. Pediatrics 2003, 111:790-794.
38. The accuracy of the CGMS in children with type 1 diabetes: Results of the Diabetes Research in Children Network (DirecNet) accuracy study. Diabetes Technol Ther 2003, 5:781-789. Diabetes Research in Children Network (DirecNet) Study Group.
39. The accuracy of the GlucoWatch G2 biographer in children with type 1 diabetes: Results of the Diabetes Research in Children Network (DirecNet) accuracy study. Diabetes Technol Ther 2003, 5:791-800. Diabetes Research in Children Network (DirecNet) Study Group.
40. Accuracy of the Glucoatch G2 Biographer and the Continuous Glucose Monitoring System during hypoglycemia: Experience of the Diabetes Research in Children Network. Diabetes Care 2004, 27:722-726. Diabetes Research in Children Network (DirecNet) Study Group.
41. American Diabetes Association position statement: Evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes and related complications. J Amer Diet Assoc 2002, 102:109-118. American Diabetes Association Task Force for Writing Nutrition Principles and Recommendations for the Management of Diabetes and Related Complications.
42. Gregory RP, Davis DL Use of carbohydrate counting for meal planning in type 1 diabetes. Diabetes Educator 1994, 20:406-409.
43. Jones TW, Porter P, Davis EA, et al. Suppressed epinephrine responses during sleep: A contributing factor to the risk of nocturnal hypoglycemia in insulin-dependent diabetes. N Engl J Med 1999, 338:1657-1662.
44. Kordonouri O, Klinghammer A, Lang EB, et al. Thyroid autoimmunity in children and adolescents with type 1 diabetes. Diabetes Care 2002, 25:1346-1350.
45. Freemark M, Levitsky LL Screening for celiac disease in children with type 1 diabetes: Two views of the controversy. Diabetes Care 2003, 26:1932-1939.
46. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics 2004, 114:555-576. National High Blood Pressure Education Program Working Group on High Blood Pressure Control in Children and Adolescents.
47. Management of dyslipidemia in children and adolescents with diabetes. Diabetes Care 2003, 26:2194-2197. American Diabetes Association.
48. Rosenbloom AL, Joe JR, Young RS, et al. The emerging epidemic of type 2 diabetes mellitus in youth. Diabetes Care 1999, 22:345-354.
49. Pinhas-Hamiel O, Dolan LM, Daniels SR, et al. Increased incidence of non-insulin-dependent diabetes mellitus among adolescents. J Pediatr 1996, 37:97-102.
50. Sinha R, Fisch G, Teague B, et al. Prevalence of impaired glucose tolerance among children and adolescents with marked obesity. N Engl J Med 2002, 346:802-810.
51. Travers SH, Jeffers BW, Bloch CA, et al. Gender and Tanner stage differences in body composition and insulin sensitivity in early pubertal children. J Clin Endocrinol Metab 1995, 80:172-178.
52. Guzzaloni G, Grugni G, Mazzilli G, et al. Comparison between beta-cell function and insulin resistance indexes in prepubertal and pubertal obese children. Metabolism 2002, 51:1011-1016.
53. Consensus Statement. Type 2 diabetes in children and adolescents. Diabetes Care 2000, 23:381-389. American Diabetes Association.
54. Type 2 diabetes in children and adolescents. Pediatrics 2000, 105:671-680. American Diabetes Association.
55. Libman I, Pietropaolo M, Arslanian S, et al. Changing phenotype: Are more youngsters with IDDM obese at onset?. Diabetologia 2001, 44:A257.
56. Katz LEL, Jawad AF, Ganesh J, et al. Parameters distinguishing childhood type 1 (TIDM) and type 2 diabetes (T2DM) at diagnosis. Diabetes 2001, 50(Suppl 2):A55.
57. Jones KL, Arslanian S, Peterokova VA, et al. Effect of met-formin in pediatric patients with type 2 diabetes: A randomized controlled trial. Diabetes Care 2002, 25:89-94.
58. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998, 317:703-713. UK Prospective Diabetes Study Group.
59. Gahagan S, Silverstein J Prevention and treatment of type 2 diabetes mellitus in children, with special emphasis on American Indian and Alaskan Native children. Pediatrics 2004, 112:e328-e347. the Committee on Native American Child Health and Section on Endocrinology, Available online at www.pediatrics.org/cgi/content/full/112/4/e328.